NextCell Pharma (NXTCL) Q1 2026 earnings summary

Executive summary

• Operating income for Q1 2026 was SEK 2.8 million, down from SEK 3.4 million year-over-year.

• Net income for Q1 2026 was SEK -10.4 million, compared to SEK -7.6 million in Q1 2025.

• Cash and cash equivalents increased to SEK 32.3 million from SEK 22.1 million year-over-year, supported by a SEK 15 million directed share issue.

• Strategic focus on international expansion, platform development, and commercialization of cell therapy for type 1 diabetes.

Financial highlights

• Net sales for Q1 2026 were SEK 2.7 million, with Cellaviva contributing SEK 2.6 million.

• Operating loss increased to SEK -10.5 million from SEK -7.8 million year-over-year.

• Earnings per share improved to SEK -0.08 from SEK -0.10 year-over-year.

• Equity ratio was 78% at quarter-end, down from 85% a year earlier.

• Total cash flow for Q1 2026 was SEK 6.3 million, compared to SEK -10.6 million in Q1 2025.

Outlook and guidance

• Focus on commercial execution of the type 1 diabetes program and scaling manufacturing capabilities.

• Anticipated release of one- and two-year clinical data for ProTrans-Young study after summer 2026.

• Long-term strategy includes expanding the clinical pipeline and achieving positive operating cash flow.